据新华社，泰国民航局宣布，1月26日起对来自印度西孟加拉邦的航班进行全面筛查，以防止尼帕病毒 输入泰国。筛查从26日0时起开始实施，同时将根据形势发展随时调整。 编辑丨瑜见 据央视新闻，近期，印度东部的西孟加拉邦出现尼帕病毒感染病例，目前已有5例确诊病例，其中包括 医护人员。据悉，近100人被要求居家隔离，感染者正在该邦首府加尔各答及周边医院接受治疗，其中 一名患者病情危重。 据世界卫生组织等机构介绍，尼帕病毒能攻击人的肺部和大脑，症状包括发烧、头疼、嗜睡、意识模糊 和昏迷，感染者的死亡率可达40%以上。这种病毒从感染到出现症状的潜伏期一般为4天至14天，最 长可达45天。目前尚无专门针对尼帕病毒的疫苗和有效疗法。 1月26日，流感板块午后拉升，截至发稿，迈克生物、凯普生物、之江生物、华兰疫苗20%涨停，达 安基因、特一药业、鲁抗医药、科华生物等涨停，智飞生物、万孚生物、康希诺、沃森生物等涨超 10%。 ...

Group 1 - The A-share market saw a significant rise in biopharmaceutical stocks, with Kang Le Wei Shi increasing by over 20% and several other companies reaching their daily limit up of 20% [1] - The outbreak of Nipah virus in West Bengal, India, has led to a human-to-human transmission risk, with a mortality rate as high as 75% and no vaccine currently available [1][2] - The Thai Civil Aviation Authority has announced comprehensive screening for flights from West Bengal, India, starting January 26, to prevent the virus from entering Thailand [1] Group 2 - Historical context shows that Nipah virus outbreaks previously occurred in Malaysia and Singapore from 1998 to 1999, resulting in over a hundred deaths and the culling of a million pigs [2] - The World Health Organization classifies Nipah virus as a deadly zoonotic virus primarily carried by fruit bats, with a transmission potential through contaminated food or direct human contact [2] - The incubation period for Nipah virus ranges from 4 to 14 days, with a maximum of 45 days before symptoms appear [2] Group 3 - Notable stock performances include: - Kang Le Wei Shi: 20.48% increase, market cap of 3.371 billion - Mai Ke Biological: 20.03% increase, market cap of 8.586 billion - Kai Pu Biological: 20.03% increase, market cap of 4.687 billion - Zhi Jiang Biological: 20.01% increase, market cap of 4.910 billion - Jin Di Ke: 13.72% increase, market cap of 2.952 billion [3] - Other companies with significant increases include Zhi Fei Biological (13.31%), Kang Xi Nuo (12.77%), and Bai Pu Sai Si (12.01%) [3]

Market Overview - The Shanghai Composite Index closed at 4141.01 points, above the annual line, with a change of 0.12% [1] - The total trading volume of A-shares reached 22,631.30 billion yuan [1] Stocks Breaking Annual Line - A total of 44 A-shares have broken above the annual line today, with notable stocks including Tongguan Mining Construction, Maike Biological, and Jiuliang Co., with deviation rates of 17.26%, 8.94%, and 8.33% respectively [1] - Stocks with smaller deviation rates that have just crossed the annual line include Laofengxiang, Shench Pharmaceutical, and Tuo Xin Pharmaceutical [1] Top Stocks by Deviation Rate - The top three stocks with the highest deviation rates are: - Tongguan Mining Construction: 21.40% increase, latest price 26.04 yuan, deviation rate 17.26% [1] - Maike Biological: 11.83% increase, latest price 13.23 yuan, deviation rate 8.94% [1] - Jiuliang Co.: 10.92% increase, latest price 31.28 yuan, deviation rate 8.33% [1] Additional Stocks with Notable Performance - Other stocks with significant performance include: - Binhang Technology: 7.30% increase, latest price 165.50 yuan, deviation rate 6.84% [1] - New Ganjing: 6.13% increase, latest price 25.81 yuan, deviation rate 5.30% [1] - Kangpu Chemical: 5.79% increase, latest price 20.64 yuan, deviation rate 5.05% [1]

有投资者在互动平台向迈克生物提问："贵公司主推的智慧化实验室，给投资者感觉像是一体化，系统 化，智能化提升医院检验中心。请问，如果医院使用贵公司产品改造升级自己的检验中心，能享受国家 和当地政府财政补贴吗？有以旧换新补贴吗？还是有其他的财政补贴支持？国家和当地政府升级基础医 疗器械补贴能享受到吗？" 针对上述提问，迈克生物回应称："尊敬的投资者，您好！因为智慧化实验室作为医院检验科的新业态 产品，不适用于传统设备的置换补贴概念；由于各地财政能力与评审周期不同，且医院须完成相关论 证、评审及申报，各医院具体情况差异较大。现阶段获得补贴的订单占比仍然较低，对公司整体业绩影 响有限。感谢您的关注与支持！" 声明：市场有风险，投资需谨慎。本文为AI基于第三方数据生成，仅供参考，不构成个人投资建议。 来源：市场资讯 ...

证券代码：300463 证券简称：迈克生物 公告编号：2026-003 迈克生物股份有限公司 关于使用部分闲置募集资金进行现金管理的进展公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导性 陈述或者重大遗漏。 迈克生物股份有限公司第六届董事会第二次会议、第六届监事会第二次会议审议通过了 《关于继续使用部分闲置募集资金进行现金管理的议案》，为提高暂时闲置募集资金的使用效 率，增加资金收益，在保证募集资金投资项目建设和募集资金正常使用的情况下，同意使用不 超过人民币6,000万元的暂时闲置募集资金进行现金管理，用于购买安全性高、流动性好、满 足保本要求的理财产品，自公司第六届董事会第二次会议审议通过之日起十二个月内有效，在 上述使用期限及额度内，资金可以循环滚动使用。闲置募集资金现金管理到期后将及时归还至 募集资金专户，同时授权公司董事长行使相关投资决策权，财务负责人办理具体相关事宜。公 司已于2025年3月7日在巨潮资讯网刊登了《关于继续使用部分闲置募集资金进行现金管理的公 告》（公告编号：2025-012）。 近日，公司使用部分闲置募集资金购买的理财产品已到期赎回，并继续使用人民币 ...

证券代码:300463 证券简称:迈克生物 公告编号:2026-002 迈克生物股份有限公司（以下简称"公司"）于近日收到四川省药品监督管理局颁发的《医 疗器械注册证》（体外诊断试剂），具体情况如下： 一、产品注册证具体情况 | 产品名称 | 注册证书 编号 | 注册 | | | 注册证有效期 | | 预期用途 | | --- | --- | --- | --- | --- | --- | --- | --- | | | | 类别 | | | | | | | 糖化血红蛋白测 定试剂盒（高效液 | 川械注准 | Ⅱ | 2026 | 年 1 | 月 8 | 日至 | 本品用于体外定量检测人体全血样本中 | | 相色谱法） | 20262400003 | | 2031 | 年 | 月 1 | 日 7 | 糖化血红蛋白的含量。 | | 糖化血红蛋白质 | 川械注准 | | | 年 | 月 | 日至 | 本品需配套本公司生产的糖化血红蛋白 | | 控品 | 20262400004 | Ⅱ | 2026 2031 | 1 年 | 8 月 1 | 日 7 | 测定试剂盒（高效液相色谱法）使用， 用于糖化血红蛋白项目的质量 ...

Group 1 - The company, Maike Bio (300463.SZ), has recently received a Medical Device Registration Certificate from the National Medical Products Administration [1] - The registered product is a cross-matching blood quality control product [1]

Group 1 - The company, Maike Bio (300463.SZ), has recently received a Medical Device Registration Certificate from the National Medical Products Administration for its product, a cross-matching blood quality control reagent [1]

Core Viewpoint - The company, Maike Biological (300463.SZ), has received a medical device registration certificate from the National Medical Products Administration for its new product, cross-matching blood quality control products, which enhances its product portfolio and market competitiveness [1] Group 1 - The newly registered product is intended for quality control in manual and fully automated blood type analysis systems during cross-matching tests [1] - The introduction of this product is expected to positively impact the company's market expansion and future operations [1] - The registration certificate enriches the company's product offerings, contributing to its overall market competitiveness [1]

Core Viewpoint - The company announced that its cross-matching quality control product has received a medical device registration certificate from the National Medical Products Administration, enhancing its product portfolio and market competitiveness [1] Group 1: Product Development - The new product is designed for use with the company's anti-human globulin (anti-IgG+C3d) testing card and is intended for quality control in manual and fully automated blood type analysis systems [1] - The product is specifically for clinical testing and is not intended for blood source screening [1] Group 2: Market Impact - The registration certificate for the new product is expected to positively influence the company's market expansion and future operations [1] - The actual sales performance of the registered product will depend on future marketing efforts, and the impact on the company's future revenue remains unpredictable [1]